Compare JFIN & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | CVRX |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.1M | 237.1M |
| IPO Year | 2018 | 2021 |
| Metric | JFIN | CVRX |
|---|---|---|
| Price | $4.89 | $7.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 40.7K | ★ 258.4K |
| Earning Date | 06-03-2026 | 05-11-2026 |
| Dividend Yield | ★ 17.47% | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $3.70 | $4.37 |
| 52 Week High | $18.70 | $11.30 |
| Indicator | JFIN | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 51.00 |
| Support Level | $3.70 | $6.74 |
| Resistance Level | $5.00 | $8.09 |
| Average True Range (ATR) | 0.21 | 0.55 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 83.19 | 79.64 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.